Related Experiment Video
Updated: Apr 5, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
[Analysis of clinical features of 6 patients with infantile type glycogen storage disease type II]
Juan Ding1, Yu Huang, Haipo Yang
1Department of Pediatrics, Peking University First Hospital, Beijing 100034, China.
Insights
Glycogen storage disease type II (GSD II) in infants presents with muscle weakness and heart issues. Early consideration of GSD II is crucial for infants with both muscular and cardiac symptoms.
Area of Science:
- Pediatric Genetics
- Metabolic Disorders
- Cardiology
Background:
- Glycogen storage disease type II (GSD II), also known as Pompe disease, is a rare inherited metabolic disorder.
- Infantile-onset GSD II is characterized by progressive muscle weakness and cardiorespiratory failure.
- Accurate and timely diagnosis is critical for managing GSD II and improving patient outcomes.
Purpose of the Study:
- To summarize the clinical features and diagnostic findings of Chinese infantile patients diagnosed with GSD II.
- To identify key clinical indicators and diagnostic markers for infantile GSD II in the Chinese population.
Main Methods:
- Retrospective review of clinical data from six Chinese infants diagnosed with GSD II between January 2012 and June 2014.
- Analysis included clinical manifestations, blood biochemistry, cardiac imaging (echocardiogram, electrocardiogram), and genetic analysis of the acid alpha-glucosidase (GAA) gene.
- Measurement of GAA enzyme activity in whole blood and GAA gene mutation analysis via PCR and direct sequencing.
Main Results:
- All six patients exhibited generalized muscle weakness, hypotonia, and developmental delays; cardiac involvement, including left ventricular hypertrophy and cardiomegaly, was present in all.
- Elevated creatine kinase (CK) levels and significantly reduced GAA enzyme activity were observed in all patients.
- Genetic analysis identified eight pathogenic mutations in the GAA gene, with classic infantile cases showing a poor prognosis and early mortality.
Conclusions:
- Infantile GSD II presents with consistent motor and cardiac manifestations, supported by biochemical, imaging, and enzymatic findings.
- The study highlights the importance of considering GSD II in infants presenting with combined muscular disease and cardiac involvement.
- Prompt diagnostic evaluation, including enzyme assays and genetic testing, is essential for early detection and management of infantile GSD II.
Objective:
To summarize clinical features and diagnosis of Chinese infantile patients with glycogen storage disease type II (GSD II).
Method:
Six infant patients with GSD II diagnosed from January 2012 to June 2014 in the Department of Pediatrics, Peking University First Hospital were enrolled into this study. Clinical information of the 6 patients, including clinical manifestation, blood biochemistry, chest X-ray, echocardiogram, electrocardiogram, acid alpha-glucosidase (GAA) activity and GAA gene mutation analysis by direct sequencing of polymerase chain reaction (PCR) product were reviewed.
Result:
Of the 6 patients, five were female and one was male, five of whom were classic infantile type while the other one was atypical. The age of onset ranged from birth to 3-month-old. All patients had varying degrees of generalized muscle weakness, hypotonia and development retardation or retrogression. Other common findings were feeding difficulties in two patients, tongue weakness in two patients, respiratory distress in four patients, macroglossia in one patient, and hepatomegaly in two patients. Left ventricular hypertrophy and cardiomegaly were obvious in all the six patients. All six patients were found to have a enlarged heart in physical examination, and three patients who underwent a chest X-ray examination had an enlarged heart shadow. Four patients who had an echocardiography were found to have myocardial hypertrophy. The electrocardiogram in three patients showed short PR intervals and high voltage. The creatine kinase (CK) levels were three to seven times elevated. The mildest elevated CK was 441 IU/L, and the highest CK level was 1 238 U/L. Assay of GAA enzyme activity in whole blood showed significantly reduced activity (1.3 nmol/ (spot·d) to 2 nmol/(spot·d)) in the patients tested. Gene sequencing in 4 patients showed 8 pathogenic mutations, including 6 missense mutations, one nonsense mutation and one frameshift mutation. The missense mutations were c.998C > A (p.Thr333Lys), c.1280T > C (p.Met427Thr), c.1760T > C (p.Leu587Pro), c.1924G > T (p.Val642Phe), c.2012T > A (p.Met671Lys) and c.2105G > A (p.Arg702His). The nonsense mutation was c2662G > T (p.Glu888X), and the frameshift mutation was c2812_2813delTG (p.Cys938fs). The 5 classic infantile patients died at the age of 7 to 22 months. The atypical infantile patient was 2 years and five months old according to our latest follow up.
Conclusion:
Infantile GSD II had similar motor manifestations and cardiac involvements, blood biochemical test, imaging findings, enzyme assays, though there were slight differences. The probability of GSD II should be taken into consideration if an infant has both muscular disease and cardiac involvement.
Related Concept Videos
Lysosomal Hydrolases
Inborn Errors of Metabolism
Parkinson's Disease: Overview
Toxidromes: Clinical Features
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

